A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined with Carboplatin and Pembrolizumab in Patients with Metastatic Triple-negative Breast Cancer (ZAP-IT)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azenosertib (Primary) ; Carboplatin (Primary) ; Pembrolizumab (Primary)
Indications Advanced breast cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms ZAP-IT

18 Dec 2024 Status changed from suspended to recruiting.
16 Sep 2024 According to Zentalis Pharmaceuticals media release, company announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on studies of azenosertib.The FDA has cleared the Company to resume enrollment in all ongoing azenosertib clinical studies with no changes in the clinical development plan.
19 Aug 2024 Status changed from recruiting to suspended.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com